Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2018, Article ID 3708637, 8 pages
Review Article

Chromium-Containing Traditional Chinese Medicine, Tianmai Xiaoke Tablet, for Newly Diagnosed Type 2 Diabetes Mellitus: A Meta-Analysis and Systematic Review of Randomized Clinical Trials

1Shandong University of Traditional Chinese Medicine, Jinan 250355, China
2Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan 250011, China
3Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan 250001, China
4Jinan Municipal Hospital of Traditional Chinese Medicine, Jinan 250012, China
5Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
6Shandong Province Qianfoshan Hospital, Shandong University, Jinan 250014, China

Correspondence should be addressed to Bo Feng; moc.621@bf_obgnef

Received 13 September 2017; Accepted 29 January 2018; Published 7 March 2018

Academic Editor: Carmen Mannucci

Copyright © 2018 Yuming Gu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Objective. Chromium-containing traditional Chinese medicine Tianmai Xiaoke tablet (TMXKT) is approved for treating newly diagnosed type 2 diabetes mellitus (T2DM) in China. This review aimed to compile the evidence from randomized clinical trials (RCTs) and quantify the effects of TMXKT on newly diagnosed T2DM. Methods. Seven online databases were investigated up to March 20, 2017. The meta-analysis included RCTs investigating the treatment of newly diagnosed T2DM, in which TMXKT combined with conventional therapy was compared with placebo or conventional therapy. The risk of bias was evaluated using the Cochrane Collaboration tool. The estimated mean difference (MD) and the standardized mean difference were within 95% confidence intervals (CI) with respect to the interstudy heterogeneity. The outcomes were measured using fasting blood glucose (FBG), 2-h postprandial blood glucose (2hPG), glycosylated hemoglobin A1c (HbA1c), and body mass index (BMI) levels. Results. TMXKT combined with conventional therapy lowered FBG level (, 95% CI −0.90 to −0.45, ), 2hPG (, 95% CI −1.86 to −0.79, ), HbA1c (MD = −0.46, 95% CI −0.57 to −0.36, ), and BMI (MD = −0.77, 95% CI −1.12 to −0.41, ). Conclusions. TMXKT combined with conventional therapy is beneficial for patients with newly diagnosed T2DM. However, the effectiveness and safety of TMXKT are uncertain because of the limited number of trials and low methodological quality. Therefore, practitioners should be cautious when applying TMXKT in daily practice. Also, well-designed clinical trials are needed in the future.